Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FB 001 - Federation Bio

Drug Profile

FB 001 - Federation Bio

Alternative Names: FB-001; FB001 - Federation Bio

Latest Information Update: 12 Dec 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Federation Bio
  • Class Bacteria; Urologics
  • Mechanism of Action Immunomodulators; Oxalate inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Hyperoxaluria

Most Recent Events

  • 08 Dec 2022 Phase-I clinical trials in Hyperoxaluria (In volunteers) in USA (PO)
  • 08 Dec 2022 Federation Bio plans to initiate part 2 of phase I trial of FB 001 in Hyperoxaluria in 2023
  • 30 Nov 2021 Federation Bio plans a clinical trial for Hyperoxaluria in the second half of 2022

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top